Moneycontrol PRO

Sharp Corporation develops Plasmacluster technology device to reduce the risk of coronavirus infection

The product could be used in hospitals, malls, theatres, offices as well as homes.

September 30, 2020 / 07:44 PM IST

Electronics goods maker Sharp Corporation has developed a device equipped with Plasmacluster technology that it claims has shown, in a research test, ability to reduce the infectious titer of the novel coronavirus (COVID-19) by more than 90 percent.

The product could be used in hospitals, malls, theatres, offices as well as homes. India has reported a total of 62,25,764 COVID-19 positive cases. A total of 97,497 people have lost their lives to COVID-19 in India so far.

Infectious titer is the concentration of viral particles that can transduce cells. Here, transduction is the process by which foreign DNA is introduced into a cell by a virus or viral vector.

Plasmacluster technology is where positively charged hydrogen and negatively charged oxygen ions are released into the air simultaneously, and the positive and negative ions instantaneously bond on the surface of airborne bacteria, fungi, viruses, allergen. This is an air purification technology that works to suppress the activity of bacteria, by breaking down proteins on their surface by a chemical reaction.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

This technology inhibits activity by breaking the protein on the cell surface which damages the cell membrane. This could effectively kill the virus.

In this study, the virus testing device was equipped with Plasmacluster technology. Then the virus was passed through the test device from a generator.


Later, the aerosolized virus was recovered after exposure to Plasmacluster ions. Then the test calculated the infectious virus titer of the recovered virus solution by a plaque assay. Assay means a standard testing to evaluate the number of infectious virus in the sample.

Covid killing

image (1)

The test, the company said, demonstrated that the virus infectious titer (number of the virus) was reduced more than 90 percent.

Sharp Corporation said in a statement that this test was accomplished in collaboration with Professor Jiro Yasuda of the National Research Center for the Control and Prevention of Infectious Diseases/Institute of Tropical Medicine, Nagasaki University, and Professor Asuka Nanbo (a board member of the Japanese Society for Virology) of the same institution.

The other collaborators were Professor Hironori Yoshiyama of the Department of Microbiology, Shimane University, Faculty of Medicine (also, a board member of the Japanese Society for Virology), and Nagasaki University, an internationally respected authority on infectious diseases research.

The outbreak of coronavirus disease (COVID-19) caused by the novel coronavirus (SARS-CoV-2) was first reported in December 2019.

Sharp said that in 2004, the company used Plasmacluster technology against feline (cat) coronavirus, a member of the Corona viridae family. In the following year of 2005, Sharp also demonstrated its effectiveness against the original SARS coronavirus (SARS- CoV), which caused the outbreak of 2002-2003 and is also genetically similar to the novel coronavirus (SARS-CoV-2).

Dr Jiro Yasuda, Professor of National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, said, "Disinfectants such as alcohol and detergents (surfactants) are well-known to be effective to reduce the risk of the virus on materials. However, for infection via aerosols (micro-droplets), there are few effective countermeasures such as a mask. Today, we demonstrated the effective inactivation of SARS-CoV-2 in airborne droplets by using Plasmacluster technology. We expect it would be useful to reduce the risk of infection in real spaces like offices, homes, medical facilities and vehicles too.”

While the device is not yet commercially available, Sharp is in talks to partner with Indian firms to offer this product in India. This could be used in commercial establishments and homes.

Moneycontrol News
first published: Sep 30, 2020 06:32 pm